Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need... Show more
APGE moved above its 50-day moving average on June 05, 2025 date and that indicates a change from a downward trend to an upward trend. In of 10 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on June 06, 2025. You may want to consider a long position or call options on APGE as a result. In of 26 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for APGE just turned positive on June 09, 2025. Looking at past instances where APGE's MACD turned positive, the stock continued to rise in of 15 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where APGE advanced for three days, in of 118 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 78 cases where APGE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The 10-day RSI Indicator for APGE moved out of overbought territory on June 16, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 12 similar instances where the indicator moved out of overbought territory. In of the 12 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where APGE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
APGE broke above its upper Bollinger Band on June 13, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.757) is normal, around the industry mean (16.366). P/E Ratio (0.000) is within average values for comparable stocks, (58.189). APGE's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.309). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (252.247).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. APGE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. APGE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Industry Biotechnology
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
GSAKX | 19.40 | 0.16 | +0.82% |
Goldman Sachs International Eq Inc A | |||
EAALX | 22.11 | 0.10 | +0.45% |
Eaton Vance Atlanta Capital Focused Gr A | |||
JHQAX | 33.01 | 0.07 | +0.21% |
JPMorgan Hedged Equity A | |||
WWSAX | 20.06 | 0.03 | +0.15% |
Keeley Small Cap Fund A | |||
SVUIX | 38.52 | 0.04 | +0.10% |
NAA SMid Cap Value Institutional |
A.I.dvisor indicates that over the last year, APGE has been loosely correlated with SYRE. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if APGE jumps, then SYRE could also see price increases.
Ticker / NAME | Correlation To APGE | 1D Price Change % | ||
---|---|---|---|---|
APGE | 100% | N/A | ||
SYRE - APGE | 54% Loosely correlated | -4.99% | ||
CRNX - APGE | 53% Loosely correlated | -0.10% | ||
ERAS - APGE | 52% Loosely correlated | N/A | ||
ATXS - APGE | 52% Loosely correlated | N/A | ||
KRYS - APGE | 50% Loosely correlated | -2.60% | ||
More |